HBV Core Curriculum 2008

Now Available!

CME-Certified Virtual Presentation:

Downloadable Slideset:

Coming Soon!

CME-Certified Virtual Presentation:

HBV Election 2008: Meet the Clinical Candidates

Now Available!

CME-Certified Virtual Presentation:

New Clinical Candidates for HBV

Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape.

CCO Slideset:

Review the new therapies for hepatitis B and the clinical issues facing these candidates. Launch Slideset

Hepatitis Annual Update 2008

Clinical Care Options' Hepatitis Annual Update offers the latest information across a wide range of hepatic issues for the optimal clinical management of your patients. Expert faculty members prepared the following CME-certified educational modules that are now available on the CCO Web site:

CME-Certified Modules:

Can Hepatitis B Be Cured? Marc G. Ghany, MD, discusses cccDNA and its role in the difficult path of obtaining a true cure for HBV infection.

Therapy of Chronic Hepatitis B: Who to Treat and When to Treat? A Case-Based Discussion Anna S. F. Lok, MD, discusses factors to consider when screening patients with chronic hepatitis B infection for treatment initiation.

Therapy of Chronic Hepatitis B: What to Choose, When to Change, and When to Stop Ira M. Jacobson, MD, reviews the latest data on which HBV therapy to choose, when to change, and when to stop.

New Data on Currently Available Hepatitis C Therapies and Their Impact on Initial Treatment Strategies (Coming Soon!) Mark S. Sulkowski, MD, reviews principles and strategies for hepatitis C treatment using currently available therapeutic agents.

	Strategies for Management of Hepatitis C Treatment Failure (Coming Soon!) Karen L. Lindsay, MD, MMM, reviews the latest data on the management of patients who were nonresponders or relapsers during HCV therapy.
	HCV Therapy: What Will the Future Look Like? (Coming Soon!) David R. Nelson, MD, reviews investigational agents and emerging treatment strategies for hepatitis C.
	Update on Autoimmune Hepatitis: Management Strategies Michael P. Manns, MD, presents updates on the identification and clinical management of autoimmune hepatitis.
	Managing the Complications of Cirrhosis Guadalupe Garcia-Tsao, MD, reviews strategies for managing the clinical complications of cirrhosis.
	Hepatitis Journal Club: Top Clinical Articles of 2007-08 (Coming Soon!) Jorge L. Herrera, MD, reviews the top hepatology articles from the past year and reviews their applications for clinical practice.

New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients

This Treatment Update is specifically designed for frontline providers, nurse practitioners, physician assistants, and others who treat patients who have been previously treated for HCV. It provides program participants with the latest data and best practices on management approaches for these patients as well as a means to synthesize these strategies through Interactive Case Challenges.

Now Available!

CME-Certified Virtual Presentation:

Downloadable Slideset:

CME-Certified Interactive Case Challenge:

Advances in HIV/HCV Coinfection

Review the most clinically relevant HIV/HCV coinfection data from the HIV/AIDS Annual Update 2008.

Now Available!

CME-Certified Module:

CCO Independent Conference Coverage of the 43rd Annual Meeting of the European Association for the Study of the Liver

Review audio Expert Highlights and Capsule Summaries of the most clinically relevant data from this important annual meeting!

CME-Certified Expert Analyses:

Update on Hepatitis B Management (Coming Soon!) Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF; Patrick Marcellin, MD; Norah Terrault, MD, MPH

Focus on Investigational HCV Agents Nezam H. Afdhal, MD, FRCPI; Ira M. Jacobson, MD; Stefan Zeuzem, MD

New Advances in Hepatitis C Alfredo Alberti, MD; Peter Ferenci, MD; Michael P. Manns, MD

Highlight on Special Hepatic Issues and Populations Robert G. Gish, MD; Josep M. Llovet, MD; Paul Martin, MD

Now Available!

CME-Certified Expert Recaps:

Update on Hepatitis B Management Daniel Shouval, MD

Focus on Investigational HCV Agents (coming soon) Ira M. Jacobson, MD

And downloadable PowerPoint slides for review or to use in your own talks!

HIV/HCV and HIV/HBV Coinfection Highlights From the CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections

Review Capsule Summaries and a CME-certified Expert Analysis of the most clinically relevant HIV/HCV and HIV/HBV coinfection data from this important annual meeting.

CCO Independent Conference Coverage of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies

Review the most clinically relevant viral hepatitis resistance data from this single-topic meeting with T. Jake Liang, MD, and Jean-Michel Pawlotsky, MD, PhD.

Now Available!

CME-Certified Conference Report:

Update on Resistance to HBV and HCV Therapy: CCO Independent Conference Report on the 2008 Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies: T. Jake Liang, MD; Jean-Michel Pawlotsky, MD, PhD

On-Treatment Management Strategies for Chronic Hepatitis B

Now Available!

CME-Certified Interactive Case Challenge:

On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy
Along with Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, choose management strategies for a patient with chronic hepatitis B receiving treatment with adefovir.

CME-Certified Virtual Presentation:

Active Management of Oral Nucleos(t)ide Analogue Therapy for Hepatitis B
Join Ira M. Jacobson, MD, as he reviews on-treatment hepatitis B virus guidelines including the relationships between early responses to oral anti-hepatitis B virus agents and future treatment outcomes.

Downloadable PowerPoint slideset available for review and use in your own educational presentations.

CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases  

CME-certified Expert Recaps:

• Clinical Updates in HBV Treatment
• Update on Investigational Agents in HCV: 2007

CME-certified Expert Analyses:

• Clinical Updates in HBV Treatment
• Advances in HCV Management Strategies With Approved Agents
• Update on Investigational Agents in HCV: 2007
• Highlight on Special Hepatic Issues and Populations

Expert Commentaries by these members of our expert faculty:

• Nezam H. Afdhal, MD, FRCPI, discusses the key studies on investigational anti-HCV agents from the Boston meeting, focusing on specifically targeted small-molecule agents and an antiparasitic demonstrating anti-HCV activity. Click here to begin.
  
  
• Raymond T. Chung, MD, reports on the most important presentations from Boston concerning predicting response to approved HCV agents and improving response of patients with poor probability of achieving sustained virologic response. In addition, he summarizes several studies of retreatment strategies for previous nonresponders. Click here to begin.
  
  
• Stephen A. Harrison, MD, LTC, MC, reviews key presentations from the Boston meeting related to insulin resistance, steatosis, and nonalcoholic steatohepatitis and their roles in the treatment of HCV. Click here to begin.
  
  
• Emmet B. Keeffe, MD, MACP, discusses several topics of interest in the field of HBV treatment, in particular, data on the use of tenofovir for the treatment of chronic HBV therapy and long-term efficacy of entecavir and baseline predictive factors for long-term treatment efficacy of telbivudine. Click here to begin.

Virologic Tools for Monitoring Patients With Chronic Hepatitis B

• Management of a 52-Year-Old HBeAg-Positive, Treatment-Naive Female Seeking Hepatitis B Therapy
  Robert G. Gish, MD, reviews the importance of HBV DNA in determining treatment candidacy and making on-treatment decisions in hepatitis B management in this Interactive Case Challenge.
  
  
• Virologic Monitoring in Hepatitis B: Tools for Determining Treatment Candidacy and Response
  Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, discusses the importance of virologic tools, with a focus on HBV DNA monitoring, for deciding when to treat and evaluating on-treatment response to oral HBV agents.

Now Online! HBV DNA Monitoring Tool for Oral Agents

Drug Resistance in Chronic Hepatitis B: From Definitions to Management Strategies

CME-Certified Module:

• Defining HBV Resistance: Interpreting and Applying Clinical Data
  Paul Martin, MD, reviews the treatment of patients with chronic hepatitis B, focusing on drug resistance.
  

CME-Certified Virtual Presentation:

• A Case-Based Approach to Managing HBV Resistance
  Emmet B. Keeffe, MD, MACP, reviews steps to prevent, identify, and manage HBV resistance to oral agents.
  

CCO PowerPoint Slideset:

• A Case-Based Approach to Managing Resistance in Chronic HBV Infection
  Download for self-study or for use in your own education presentations.

New Management Strategies for HCV Nonresponders and Relapsers

CME-certified Module Understanding HCV Nonresponse and Identifying Candidates for Retreatment Mitchell L. Shiffman, MD, discusses types of virologic response in hepatitis C virus–infected patients to interferon- and ribavirin-based regimens and explains how to identify good candidates for retreatment following failure to achieve sustained virologic response. CME-certified Downloadable PowerPoint Slideset New Management Strategies for HCV Nonresponders and Relapsers  Mitchell L. Shiffman, MD, reviews the various types of virologic response in patients treated for hepatitis C virus infection, discusses what factors are associated with better responses, and summarizes the most recent data available on various retreatment strategies.

CME-certified Interactive Case Challenge Retreatment of a Patient With Chronic HCV Infection and Previous Treatment Failure Tarek Hassanein, MD, describes retreatment decisions for patients with chronic hepatitis C who have failed to achieve sustained virologic response with previous interferon- and ribavirin-based regimens.

• Choosing First-Line Therapy in Chronic Hepatitis B
  Kris Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B. Also, access Interactive Case Challenges and a Virtual Presentation.
  
• Advanced Topics in Hepatitis C Management: Tools for Nurse Practitioners and Physician Assistants
  Review educational modules, case challenges and downloadable slides. An HCV RNA Monitoring Tool is also available.
  

• Case Debates With the Experts: Applying the Updated Practice Guidelines to the Management of Hepatitis B
  Access three Interactive Case Challenges and three downloadable slidesets.
  
  
• The Future of HCV: Small Molecules in Development for Chronic Hepatitis C
  Access three educational modules by Raymond T. Chung, MD, Gary L. Davis, MD, and Kenneth E. Sherman, MD, PhD.
  

• 2008 Annual Meeting of the European Association for the Study of the Liver*
  
• 2007 Annual Meeting of the American Association for the Study of Liver Diseases*
  
  

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

• On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy
  
• Management of an Overweight Man With Genotype 1 Hepatitis C 
  
• Management of a Treatment-Naive, 54-Year-Old Woman Experiencing Anemia and Virologic Breakthrough During HCV Therapy

Topics

• Fibrosis and Cirrhosis
• HBV
• HCV
• Hepatocellular Carcinoma
• HIV Coinfection
• Nash, ALD, etc.
• Other Hepatitis Viruses
• Transplantation

Resources

• Advanced Search
• Case Challenges
• Animations
• Live Events
• Slide Download Library
• Interactive Tools
• Free Bookstore

Switch to Tenofovir-Based Regimen Results Effective for Hepatitis B Patients With Persistent Viremia Receiving Adefovir

In this double-blind, randomized trial, 2 tenofovir-containing regimens were shown to significantly decrease HBV DNA at 48 weeks in patients who were previously unresponsive to adefovir therapy. More

Click here for the slide library.

Click here to visit the bookstore.

Maria Sjogren, MD, discusses the treatment management options for patients not achieving HCV RNA suppression after 24 weeks of peginterferon alfa-2b/ribavirin.

Click here for more cases.

Click here for more tools.